In this three-part Drug Hunter special on Artificial Intelligence and Machine Learning in Drug Discovery, we cover:

• Different ways companies are applying AI/ML to drug discovery
• Molecules from AI/ML discovery programs in clinical development
• Molecules from AI/ML repurposing programs in clinical development
• A round-up of companies with recent updates in the field

On Halloween we polled the audience on what keeps them up at night in drug discovery. Non-monitorable tox is pretty spooky!

1. How Does This Thing Get in the Brain??
2. Synthetic Access to Stable Atropisomers in Drug Discovery
3. Molecules of the Month – September 2022
4. Molecules of the Month Runners-Up – August 2022 (p)
5. New FDA Approval: Deucravacitinib (Sotyktu) (p)
6. Voxelotor, A $5.4 Billion Reversible Covalent Aldehyde (p)
7. Computational Partnership in Small Molecule Drug Discovery
8. An Intracellular Enzyme Drug via Endocytosis: Olipudase Alfa (p)
9. Molecules of the Month - Aug 2022 (p)
10. Drug Discovery Technology Review: 2022Q2/Q3 (p)
11. EMA Approval: Lenacapavir (Sunlenca) (p)
12. The 27 Lead Drug Molecules Acquired from Biotechs in 2021 (p)

Aqemia is a pharmatech company generating one of the world's fastest-growing drug discovery pipelines. Our mission is to design innovative drug candidates for dozens of critical diseases. Our differentiation lies in our unique quantum and statistical mechanics algorithms that comes from 10 years of academic research in Oxford, Cambridge, and CNRS. This breakthrough technology predicts the efficacy of molecules 10,000 times faster and more accurately than what exists today on the market, from the nature and position of atoms. It fuels a generative AI to design novel drug candidates with better chances of success. We are developing a massive pipeline of wholly-owned drug discovery projects, in order to generate dozens of up to $1B-worth Biotechs. 

In only 3 years, the company achieved key milestones, such as:

• Built a team of 45 top-tier people at the crossroads of Chemistry and Machine Learning.

• Collaborating with several top Big Pharmaceutical companies such as Sanofi, Servier and Janssen with 2M$ in revenues, and renewed our two first contracts after promising results.

• Started multiple internal pipeline projects, with early good results to build on.

• Fundraised $12M with Eurazeo (largest European investment fund) and Elaia Partners (French first deeptech VC fund).